Efficacy of fingolimod and interferon beta-1b on cognitive, MRI, and clinical outcomes in relapsing–remitting multiple sclerosis: an 18-month, open-label, rater-blinded, randomised, multicentre study (the GOLDEN study)

Cognitive impairment (CI) affects 40–65% of multiple sclerosis (MS) patients. This study attempted evaluating the effects of fingolimod and interferon beta-1b (IFN β-1b) on CI progression, magnetic resonance imaging (MRI) and clinical outcomes in relapsing–remitting MS (RRMS) patients over 18 months...

Descripción completa

Detalles Bibliográficos
Autores principales: Comi, Giancarlo, Patti, Francesco, Rocca, Maria Assunta, Mattioli, Flavia Caterina, Amato, Maria Pia, Gallo, Paolo, Centonze, Diego, Pozzilli, Carlo, Saccà, Francesco, Bergh, Florian Then, Bartezaghi, Marta, Turrini, Renato, Filippi, Massimo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2017
Materias:
Original Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5688215/
https://www.ncbi.nlm.nih.gov/pubmed/29063244
http://dx.doi.org/10.1007/s00415-017-8642-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5688215/
https://www.ncbi.nlm.nih.gov/pubmed/29063244
http://dx.doi.org/10.1007/s00415-017-8642-5

Ejemplares similares